Dive into the archives.
- Newly Published Data Show Copaxone Promoted Remyelination of Damaged Axons
The purpose of this study was to examine the effect of glatiramer acetate on oligodendrogenesis (the formation of myelin-producing glial cells in the central nervous system) and myelin formation in damaged nerve cells in mice
The mice were subjected to lysolecithin-induced demyelination of the spinal cord, then treated daily for seven days with a 2mg injection [...]
- Teva Sues Mylan Over MS Drug Copaxone
Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the [...]
- What’s the Point of Extavia?
Featured Story Oct. 16, 2009
By Angela Maas, Managing Editor
Another drug in the self-injected multiple sclerosis (MS) class recently came onto the marketplace. But many within the pharmaceutical industry are saying that other than giving Novartis an entry into the MS market before its [...]
- Copaxone Used for First-Episode/CIS Halves MS Risk
PARIS — Early treatment with a key drug to fight multiple sclerosis (MS) nearly halves the risk of progression to the full-blown disease, according to a study published online on Wednesday by The Lancet.
The treatment, glatiramer acetate, marketed as Copaxone, was tested in 16 countries among 481 patients with a telltale lesion in the central [...]
- Don’t Hold Your Breath For Generic Avonex
September 16, 2009 — 11:47am ET | By George Miller
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the form of a newly issued method-of-use patent, which also covers Avonex treatment of multiple [...]
- Biogen Reports 2 More Cases of PML with Tysabri
By THOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan PLC, the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Avonex Pre-Filled Syringes and My Wretched Side Effects
Sometimes interferons, including AVONEX, make people feel sad. If you are taking AVONEX, and feel unusually sad, you should tell a family member or friend right away and call your healthcare provider as soon as possible.
Some people have had severe allergic reactions, a drop in their red or white blood cell levels, a drop in [...]
- Mitoxantrone is highly efficient in suppressing MS
Mitoxantrone: highly efficient escalation therapy in multiple sclerosis
According to data supplied by the German Multiple Sclerosis Society’s national MS register (DMSG – Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years. Numerous studies have shown that it is highly efficient in suppressing disease [...]
- Generic Betaseron Wins FDA Approval
By Eva von Schaper
Aug. 17 (Bloomberg) — Novartis AG won U.S. Food and Drug Administration approval to sell its Extavia multiple sclerosis treatment, its brand of Bayer AG’s Betaseron.
Extavia, a form of interferon beta-1b, can be used in patients with early and relapsing forms of multiple sclerosis, Basel, Switzerland-based Novartis said in a statement today.
Selling [...]
